Business Wire

NY-UNIFRAX

9.9.2021 13:02:10 CEST | Business Wire | Press release

Share
SiFAB™ by Unifrax Will Be Featured at The Battery Show North America

Unifrax , a leading manufacturer of high-performance specialty materials will feature their latest innovation, SiFAB™ Silicon Fiber Anode Battery Technology , at next week’s Battery Show in Novi, Michigan. Unifrax launched SiFAB earlier this year, and will feature the new silicon fiber technology during a technical presentation and exhibit during this year’s The Battery Show and Electric & Hybrid Vehicle Technology Expo at Suburban Collection Showplace, September 14-16.

Bruce Zoitos, senior scientist and manager, materials research, Unifrax, will present data obtained following advanced testing of SiFAB, which has demonstrated promising performance in multiple battery systems. SiFAB, uniquely structured for high-capacity performance, enables significantly higher energy density in lithium-ion battery systems and has successfully been tested with incremental Si loadings of greater than 40 percent. Zoitos will present these findings during a technical session on Wednesday, September 15 at 2:30 p.m. in the Crystal Room.

“Lithium-ion batteries are playing a pivotal role in our everyday life,” said Zoitos. "Along with greater energy density, SiFAB will provide faster charges and longer battery life for applications including electric vehicles, portable electronics, power tools, energy grid storage, and aerospace. With SiFAB, our recent testing shows our technology can provide a drop-in solution that can be incorporated as early as 2022, enabling better and longer-performing applications.”

The data, collected in part by Wildcat Discovery Technologies, and the Battery Innovation Center, support SiFAB’s promising performance with significantly higher capacity and fast charging capability in various electrode formulations.

According to advanced testing performed in 2021, SiFAB has demonstrated:

  • Reversible capacity greater than 1,000 mAh/g enabling gravimetric energy density improvement over graphite up to 20 percent
  • Robust performance in various electrode formulations which allows design flexibility to cell makers and OEMs
  • Proven high-rate charge and discharge performance up to 4C
  • Proven high temperature performance at 45°C
  • Stable cycling with high Si loadings and minimal volume expansion. Cycling of these batteries is ongoing
  • SiFAB drops into existing manufacturing process; SiFAB has been successfully applied in roll-to-roll processes in standard manufacturing scenarios

“After working with reputable battery labs and partners to test SiFAB, we’re excited to share SiFAB testing results at The Battery Show next week,” said Chad Cannan, senior vice president of research and development, Unifrax. “Our data shows SiFAB delivers strong performance in realistic cell conditions and real-world applications. With SiFAB’s promising performance, and Unifrax’s ability to scale up manufacturing with our first SiFAB manufacturing line being built at our Indiana manufacturing site now, our plan is on track for producing tens of metric tons in early 2022 with hundreds of metric tons capacity planned for 2023, making SiFAB a reality for customers,” said Cannan.

In addition to the SiFAB technical session with Bruce Zoitos, Unifrax will be available at booth #1431 during the 2021 Battery Show September 14-16, to discuss SiFAB technology with interested attendees.

To learn more about SiFAB, and to request a sample, visit www.sifab.com .

About Unifrax

Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com . For updates, follow us on Twitter , LinkedIn and Facebook .

About Clearlake

Clearlake Capital Group, L.P. is a leading investment firm founded in 2006 operating integrated businesses across private equity, credit and other related strategies. With a sector-focused approach, the firm seeks to partner with experienced management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S. ® The firm’s core target sectors are industrials, technology and consumer. Clearlake currently has approximately $39 billion of assets under management, and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release

Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng

vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye